D
David Z.I. Cherney
Researcher at University Health Network
Publications - 322
Citations - 12258
David Z.I. Cherney is an academic researcher from University Health Network. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 43, co-authored 235 publications receiving 8019 citations. Previous affiliations of David Z.I. Cherney include Toronto General Hospital & University of Toronto.
Papers
More filters
Journal ArticleDOI
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z.I. Cherney,Bruce A. Perkins,Nima Soleymanlou,Maria Maione,Vesta Lai,Alana Lee,Nora M. Fagan,Hans-Juergen Woerle,Odd Erik Johansen,Uli C. Broedl,Maximilian von Eynatten +10 more
TL;DR: Short-term treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin attenuated renal hyperfiltration in subjects with T1D, likely by affecting tubular-glomerular feedback mechanisms.
Journal ArticleDOI
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
TL;DR: Some diabetes clinical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic targets and who have prevalent atherosclerotic cardiovascular disease.
Journal ArticleDOI
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon,Richard Pratley,Samuel Dagogo-Jack,James P. Mancuso,Susan Huyck,Urszula Masiukiewicz,Bernard Charbonnel,Robert Frederich,Silvina Gallo,Francesco Cosentino,Weichung Shih,Ira Gantz,Steven G. Terra,David Z.I. Cherney,Darren K. McGuire +14 more
TL;DR: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events.
Journal ArticleDOI
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L. Bhatt,Michael Szarek,Bertram Pitt,Christopher P. Cannon,Lawrence A. Leiter,Darren K. McGuire,Julia B. Lewis,Matthew C. Riddle,Silvio E. Inzucchi,Mikhail Kosiborod,David Z.I. Cherney,Jamie P. Dwyer,Benjamin M. Scirica,Clifford J. Bailey,Rafael Diaz,Kausik K. Ray,Jacob A. Udell,Renato D. Lopes,Pablo Lapuerta,P. Gabriel Steg +19 more
TL;DR: In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart Failure than placebo but was associated with adverse events.
Journal ArticleDOI
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K. McGuire,Weichung Shih,Weichung Shih,Francesco Cosentino,Bernard Charbonnel,David Z.I. Cherney,Samuel Dagogo-Jack,Richard E. Pratley,Michelle Greenberg,Shuai Wang,Susan Huyck,Ira Gantz,Steven G. Terra,Urszula Masiukiewicz,Christopher P. Cannon +14 more
TL;DR: This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.